Past studies have revealed sophisticated correlations between mutations and tumor prognoses, e.g., TP53 mutations have significant associations with poor outcomes in kidney renal clear cell carcinoma, head and neck squamous cell carcinoma, and acute myeloid leukemia, as well as improved outcomes in ovarian serous cystadenocarcinoma [41]. This evidence concerns the gene TP53 and acute myeloid leukemia.